Morgan Stanley raises CSL price target 9.9% to A$200
Morgan Stanley raised its price target for CSL by 9.9% to A$200 per share.
Story updates
12:21:58 AM UTC
SquawkNews
Pharmaceutical company CSL's bull at Morgan Stanley raises its price target by 9.9% to A$200.00/share after factoring in the benefits of recent partnerships aimed at bolstering its pipeline of new treatments. CSL has announced partnerships with VarmX and Alentis over the past year or so. MS says it…